CNBC
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
Shares of Eli Lilly closed more than 9% higher on Thursday. The company also raised its full-year adjusted earnings to a range of $16.10 to $16.60, up from a previous guidance of $13.50 to $14 ...
2 days ago